Rebound pain after peripheral nerve block
Conditions
Interventions
Tegileridine group:Tegileridine-based PCIA
Morphine group:Morphine-based PCIA
Sponsors
The First Affiliated Hospital of the University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18–65 years, either sex; 2.American Society of Anesthesiologists (ASA) physical status I–III; 3.Scheduled for unilateral lower extremity fracture open reduction and internal fixation with single-shot peripheral nerve block; 4.Planned use of postoperative intravenous patient-controlled analgesia within 48 hours; 5.Willing to participate and sign informed consent;
Exclusion criteria
Exclusion criteria: 1.Planned continuous peripheral nerve block; 2.Allergy or contraindication to study drugs; 3.History of chronic pain; 4.Multiple trauma patients; 5.Use of opioids, sedatives, antipsychotics, muscle relaxants, anxiolytics or alcohol within 1 week; 6.History of drug or alcohol abuse or dependence; 7.CYP2D6 poor metabolizers or relevant inhibitor use; 8.CYP3A4 strong inhibitor or inducer use; 9.Adrenal insufficiency or long-term steroid use; 10.Severe hepatic impairment (Child-Pugh class C); 11.Uncontrolled severe cardiovascular, respiratory, neurological or psychiatric disease; 12.Pregnancy or lactation; 13.Any condition deemed unsuitable by investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of rebound pain after peripheral nerve block; | — |
Secondary
| Measure | Time frame |
|---|---|
| Summed Pain Intensity Difference (SPID);Number of PCIA demands;Incidence of adverse events;Rescue analgesic use;Patient satisfaction with analgesia; | — |
Countries
China
Contacts
Public ContactWei Gao
The First Affiliated Hospital of the University of Science and Technology of China
Outcome results
None listed